Bactiguard’s central venous catheters approved in Mexico
The product approval for Bactiguard's central venous catheters has been announced by the Mexican Ministry of Health. This provides new opportunities for Bactiguard in providing effective infection prevention for the most vulnerable patients in the second biggest market in Latin America.
“We are finally through the registration process in Mexico, which started more than two years ago. With the new product approval, we can provide a more comprehensive range of products for effective infection prevention to the most vulnerable patients,” says Jonas Östregård, SVP Sales & Marketing.
“Most countries are facing major societal challenges, including hospital acquired infections, and there is a growing need for preventive solutions. With the full Bactiguard portfolio for infection protection available, we are convinced that the hospitals in Mexico will be able to reduce infections and limit the use of antibiotics,” Jonas Östregård continues.
In 2016 Bactiguard received Mexican product approval for its infection preventive urinary catheters (BIP Foley) and in 2018 for endotracheal tubes, (BIP ETT), and sales started in 2017.
Catheter related bloodstream infections (CBRSI), also known as Central Line Associated Bloodstream Infections (CLABSI), account for a large proportion of healthcare associated infections (HAI) in patients using medical devices, such as central venous catheters (CVC). These infections can lead to serious complications, causing patient suffering as well as increased mortality and healthcare costs. In addition, these infections are often treated with antibiotics, which increase the risk of emergence and spread of multi-resistant microbes.
A common complication during treatment with CVCs, apart from infections, is thrombosis. An ex vivo study using Thrombin-Anti-Thrombin (TAT) as a marker for the risk of developing thrombosis, showed lower TAT levels when using BIP CVC compared to uncoated catheters, which may indicate a lower risk of developing thrombosis.
. Klevens RM et al, Public Health Rep. 2007 Mar-Apr;122(2):160-6
. Vafa Homann et al. 2015, J. Biomed. Mater. Res. Part B Appl. Biomater.
For further information, please contact:
Jonas Östregård, SVP Sales & Marketing, cell phone: +46 70 521 13 88
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives at www.bactiguard.com